New malaria vaccine regimen tested for safety in UK adults
NCT ID NCT06320535
First seen Nov 17, 2025 · Last updated May 14, 2026 · Updated 25 times
Summary
This early-stage study tests whether a new way of giving the R21/Matrix-M™ malaria vaccine is safe and creates a strong immune response. About 36 healthy adults in the UK who have never had malaria will receive either the standard vaccine schedule or an experimental one with increasing doses. The goal is to find a better vaccination plan to protect against malaria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA FALCIPARUM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre for Clinical Vaccinology and Tropical Meducine, Churchill Hospital, University of Oxford
Oxford, Oxfordshire, OX3 7LE, United Kingdom
-
University Hospitals Bristol and Weston NHS Foundation Trust
Bristol, BS2 8HW, United Kingdom
Conditions
Explore the condition pages connected to this study.